Adtran and Sonic Fiber Internet partner to deliver 50G PON connectivity across California
News summary: 50G PON services will address soaring bandwidth demand from data-intensive applications, streaming and connected devices Sonic’s high-speed rollout will empower households and businesses, driving next-generation digital experiences Designed for coexistence with GPON and XGS-PON, Adtran’s 50G PON supports streamlined network upgrades without disruption
Adtran today announced its strategic collaboration with Sonic Fiber Internet to bring 50Gbit/s passive optical network (50G PON) connectivity to California. The partnership is a proactive step to ensure Sonic continues to deliver ultra-fast broadband services that meet the growing demand for higher capacity and faster speeds across the US. By leveraging Adtran’s 50G PON technology, Sonic aims to lead the industry in connectivity standards for both residential and business customers, enabling a range of applications from smart home integration and advanced entertainment streaming to frictionless remote work and high-speed business connectivity. The technology coexists with GPON and XGS-PON, providing a seamless and cost-efficient upgrade path with no service disruption, while future-proofing the network and ensuring scalability for evolving digital needs. It also supports Combo PON setups, integrating multiple generations of fiber technology to fully maximize deployment flexibility.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241101302692/en/
Adtran’s 50G PON technology will help Sonic set a new standard for ultra-fast connectivity in the US. (Photo: Business Wire)
“Our partnership with Adtran marks a major milestone in the evolution of ultra-fast connectivity in California. By developing the state’s first 50G PON network, we’re laying the foundation to meet the rapidly growing demands of emerging technologies and data-intensive applications, as well as supporting emerging standards like Wi-Fi 7, Wi-Fi 8 and beyond,” said Stephen Bradley, VP of sales and marketing at Sonic Fiber Internet. “This collaboration keeps Sonic ahead of industry trends and consumer needs, ensuring our customers always receive the fastest and most reliable internet experience available at the lowest price. It sets the stage for a new era of connectivity, empowering our customers to embrace the future with confidence.”
Adtran and Sonic are joining forces to advance state-of-the-art FTTX connectivity that delivers symmetrical speeds of 50Gbit/s, ensuring bandwidth capacity for even the most demanding applications. Adtran and Sonic’s 50G PON partnership will support targeted rollouts in high-demand areas while providing cost-effective scalability for future growth. The new technology will also help reduce operational costs and environmental impact, making it a sustainable choice for network evolution.
“With their forward-thinking approach to advancing high-speed broadband, it’s no surprise that Sonic is taking a leading role with 50G PON. Our partnership will drive future-ready infrastructure to meet both today’s and tomorrow’s connectivity demands, further strengthening Sonic’s position as a pioneer in ultra-fast, highly reliable internet services,” commented Christoph Glingener, CTO of Adtran. “By integrating with existing fiber networks, 50G PON enables incremental upgrades that minimize disruption while allowing Sonic to stay ahead of market trends. This approach supports a variety of use cases, from enhancing connectivity in homes and high-density residential areas to powering enterprise campuses and public Wi-Fi expansion. It also future-proofs the network for emerging Wi-Fi standards and smart city infrastructure, driving down costs and accelerating widespread adoption.”
For more information on Adtran and Sonic’s 50G PON plans, please register for a joint webinar to be held on November 14.
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of Adtran Networks SE, formerly ADVA Optical Networking SE. Find more at Adtran, LinkedIn and X.
Published by
ADTRAN Holdings, Inc.
www.adtran.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20241101302692/en/

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Andersen Consulting tilføjer samarbejdsfirmaet Codezilla7.12.2025 21:19:00 CET | Pressemeddelelse
Andersen Consulting styrker sine kompetencer inden for digital transformation gennem en samarbejdsaftale med Codezilla, et firma med hovedsæde i Rumænien, der udvikler specialtilpasset software. Codezilla specialiserer sig i at udvikle skræddersyede softwareprodukter, der løser forretningsmæssige udfordringer gennem en tværfaglig tilgang, som kombinerer softwareudvikling med dybdegående marketingekspertise. Med over 30 år på markedet fungerer firmaet som implementerings- og digital konsulentressource for reklamebureauer, samtidig med at de arbejder med en bred kundebase, herunder virksomheder inden for sundhedssektoren og medicinsk udstyr. Codezillas interne teams strækker sig over teknik, design og strategi og leverer omnichannel-løsninger til både regionale og globale kunder. "Vi tror på, at fantastisk software er resultatet af solid ingeniørkunst og disciplineret eksekvering," udtaler Sebastian Doroftei, administrerende direktør for Codezilla. "Vores samarbejde med Andersen Consulti
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 17:00:00 CET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom